Breast cancer survivors may have increased risk of thyroid cancer
the ONA take:
According to preliminary findings presented at the annual meeting of the Endocrine Society in San Diego, California, researchers at Columbia University Medical Center in New York City have found that female breast cancer survivors may be at an increased risk for developing thyroid cancer.
For the study, researchers analyzed government data from over 700,000 American women treated for breast cancer.
They found that women had a higher-than-average risk for developing thyroid cancer, mostly within 5 years of the breast cancer diagnosis.
The researchers estimated that a 40-year-old female breast cancer survivor's risk of developing thyroid cancer in the next 10 years was 16% and 12% for a 50-year-old woman, compared with 0.3% for the average U.S. woman.
The findings do not make it clear what causes the association, but it may be related to the thyroid gland being exposed to radiation treatment for breast cancer. In general, the incidence of thyroid cancer is increasing in the United States, possibly due to better detection with the increasing use of thyroid ultrasound.
Female breast cancer survivors may be at an increased risk for developing thyroid cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|